Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

WinHealth Pharma Licenses World’s First Oral Arsenic Trioxide Arsenol for Mainland China APL Treatment

Fineline Cube Apr 14, 2026
Company Deals

Thermo Fisher’s PPD Secures 270M-Patient HealthVerity Dataset for AI-Driven Clinical Trial Optimization

Fineline Cube Apr 14, 2026
Company Deals

China Resources and Roche Partner on Trastuzumab Emtansine Commercialization to Expand Breast Cancer ADC Access

Fineline Cube Apr 14, 2026
Company Deals

CTTQ and Teva Partner on Treanda Commercialization to Expand Bendamustine Access in China’s NHL Market

Fineline Cube Apr 14, 2026
Company Deals

Erasca Exercises Option to Secure Global Rights to Pan-RAS Molecular Glue ERAS-0015 from Joyo Pharmatech

Fineline Cube Apr 14, 2026
Policy / Regulatory

FDA Issues Draft Guidance for Genome Editing Therapy Safety Assessment Using Next-Generation Sequencing

Fineline Cube Apr 15, 2026
Company Drug

Laekna Therapeutics Reports Breakthrough Phase III Results for LAE002 AKT Inhibitor in HR+/HER2- Breast Cancer

Fineline Cube Apr 15, 2026
Company Drug

Xuanzhu Biopharma Receives NMPA Approval for Phase III Trial of Anaprazole-Based Quadruple Therapy Against H. pylori

Fineline Cube Apr 15, 2026
Company Deals

China’s Tigermed Taps Veeva Systems for Advanced Electronic Data Acquisition

Fineline Cube May 24, 2024

Veeva Systems, a U.S.-based life science cloud software specialist, has entered into a partnership with...

Company Drug

Keymed Biosciences’ Stapokibart Earns Priority Review for Chronic Sinusitis Treatment in China

Fineline Cube May 24, 2024

Keymed Biosciences Inc., (HKG: 2162), a biopharmaceutical company based in China, has announced that its...

Company Drug

Sino Biopharmaceutical’s Benmelstobart Shows Positive Results in RCC Combination Therapy Study

Fineline Cube May 24, 2024

Sino Biopharmaceutical Ltd (HKG: 1177), a leading biopharmaceutical company based in China, has announced positive...

Company Deals

Boehringer Ingelheim and Peking University Deepen Partnership with Joint Drug Research Lab

Fineline Cube May 24, 2024

Boehringer Ingelheim, a major German pharmaceutical company, has entered into an agreement with China’s Peking...

Company Deals

Eli Lilly Partners with Aktis Oncology to Advance Cancer Radiopharmaceuticals

Fineline Cube May 23, 2024

Eli Lilly and Company (NYSE: LLY) has announced a strategic partnership with Aktis Oncology, a...

Company Deals

MSD Partners with Dragonfly Therapeutics to Combine Keytruda with NK Cell Engager in Cancer Treatment

Fineline Cube May 23, 2024

Merck, Sharp & Dohme (MSD; NYSE: MRK), the producer of the leading checkpoint inhibitor Keytruda...

Company Deals

Alvotech and Dr. Reddy’s Partner to Challenge Amgen’s Denosumab with Biosimilar AVT03

Fineline Cube May 23, 2024

Amgen’s (NASDAQ: AMGN) dominance in the bone treatment market with its blockbuster drugs Xgeva and...

Company Deals

Legend Biotech Gains Access to MaxCyte’s Cell Engineering Tech with New License Agreement

Fineline Cube May 23, 2024

China’s Legend Biotech Corporation (NASDAQ: LEGN) has entered into a strategic platform license (SPL) agreement...

Policy / Regulatory

China’s NMPA and NHC Tighten Control on Psychotropic Substances with New Regulations

Fineline Cube May 23, 2024

The National Medical Products Administration (NMPA) and the National Health Commission (NHC) of China have...

Company

Jiuzhou Pharmaceutical Expands Global Footprint with $9.5 Million German CRO Subsidiary

Fineline Cube May 23, 2024

Zhejiang Jiuzhou Pharmaceutical Co., Ltd (SHA: 603456), a leading Chinese pharmaceutical company, has announced plans...

Company Drug

Fosun Pharmaceutical’s Humira Biosimilar Gains New Indications with NMPA Approval

Fineline Cube May 23, 2024

Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) has announced that its biosimilar...

Company Drug

Simcere Pharmaceutical’s Quviviq Secures Hong Kong Marketing Approval for Insomnia Treatment

Fineline Cube May 23, 2024

Jiangsu Simcere Pharmaceutical Co., Ltd (HKG: 2096) has announced that it has received marketing approval...

Company Drug

NK CellTech’s NK-Cell Therapy Gets Green Light from China’s NMPA for Solid Tumor Treatment

Fineline Cube May 23, 2024

NK CellTech, a Shanghai-based developer of natural killer (NK) cell therapies, has announced that it...

Company Deals Digital

C.Q. Pharmaceutical and JD.com Join Forces to Revolutionize Pharmaceutical Supply Chain

Fineline Cube May 23, 2024

C.Q. Pharmaceutical Holding Co., Ltd (SHE: 000950), a prominent Chinese pharmaceutical company, has announced a...

Company Deals

AstraZeneca Partners with Nona Biosciences in Multimillion-Dollar Monoclonal Antibody Agreement

Fineline Cube May 23, 2024

HBM Holdings Ltd’s (HKG: 2142) wholly-owned subsidiary, Nona Biosciences, has announced a significant licensing agreement...

Company Deals

Fosun Diagnostics and Jointown Medical Ink Partnership to Boost Medical Supply Chain

Fineline Cube May 23, 2024

Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196), a leading healthcare conglomerate in...

Company Drug

Laekna Therapeutics’ mCRPC Drug Combo Advances to Phase III with FDA Approval

Fineline Cube May 23, 2024

Laekna Therapeutics Shanghai Co., Ltd, a biopharmaceutical company based in China, has announced that it...

Company Drug

Changchun High & New Technology Industries Gets Green Light for Jinnamab Clinical Trial

Fineline Cube May 23, 2024

Changchun High & New Technology Industries (Group) Inc. (SHE: 000661), a leading biopharmaceutical company based...

Company Deals

Amoy Diagnostics Teams Up with Boehringer Ingelheim for CDx Developmen

Fineline Cube May 23, 2024

Amoy Diagnostics Co., Ltd (AmoyDx, SHE: 300685), a prominent player in China’s tumor precision medicine...

Company Medical Device Policy / Regulatory

FDA Alert: Chinese Syringe Maker Jiangsu Shenli Initiates Voluntary Recall

Fineline Cube May 23, 2024

This week, the US Food and Drug Administration (FDA) provided a status report on its...

Posts pagination

1 … 341 342 343 … 651

Recent updates

  • Laekna Therapeutics Reports Breakthrough Phase III Results for LAE002 AKT Inhibitor in HR+/HER2- Breast Cancer
  • Johnson & Johnson Reports Strong Q1 2026 Sales Growth Despite Net Earnings Decline; Raises Full-Year Guidance
  • Xuanzhu Biopharma Receives NMPA Approval for Phase III Trial of Anaprazole-Based Quadruple Therapy Against H. pylori
  • Shanghai Henlius Biotech Launches Phase I Trial for HLX05-N Cetuximab Biosimilar in Metastatic Colorectal Cancer
  • Beijing Sinotau’s Prostate Cancer Diagnostic Agent XTR020 Receives NMPA Review Acceptance
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Laekna Therapeutics Reports Breakthrough Phase III Results for LAE002 AKT Inhibitor in HR+/HER2- Breast Cancer

Company

Johnson & Johnson Reports Strong Q1 2026 Sales Growth Despite Net Earnings Decline; Raises Full-Year Guidance

Company Drug

Xuanzhu Biopharma Receives NMPA Approval for Phase III Trial of Anaprazole-Based Quadruple Therapy Against H. pylori

Company Drug

Shanghai Henlius Biotech Launches Phase I Trial for HLX05-N Cetuximab Biosimilar in Metastatic Colorectal Cancer

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.